Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
GoodRx Holdings, Inc. reported the results of its annual stockholder meeting held on June 16, 2026. Class A stockholders had one vote per share and Class B stockholders had ten votes per share as of the April 20, 2026 record date.
A total of 89,932,951 Class A shares and 233,964,187 Class B shares were represented, accounting for approximately 99.4% of the combined voting power. Stockholders elected Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre as Class III directors.
They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers.
REY-GIRAUD AGNES reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Agnes Rey-Giraud reported an equity compensation grant in the form of restricted stock units covering 73,434 shares of Class A common stock. These units were awarded at no cash cost to her and represent a contingent right to receive shares in the future.
The restricted stock units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the company’s 2027 Annual Meeting of Stockholders, assuming she continues her service through that date. Following this grant, she holds 426,286 shares of Class A common stock directly, reflecting a routine director compensation award rather than an open-market purchase.
Kennedy Kelly J. reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Kelly J. Kennedy received an equity award of 73,434 restricted stock units (RSUs) of Class A common stock. The RSUs were granted at no cash cost and each unit represents a right to one share. They vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to continued service. Following this grant, Kennedy holds 207,645 Class A shares/units directly.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant on Class A common stock. He received 73,434 deferred stock units, each representing a right to one share at no cash cost. These units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the company’s 2027 annual stockholders’ meeting, subject to his continued service.
The deferred stock units will be settled in shares upon the earliest of December 31, 2029, separation from service, a change in control, death, or disability under the company’s director deferred compensation plan. After this grant, Hirsch directly holds 320,936 Class A shares. Additional Class A shares are held indirectly through grantor retained annuity trusts and by his spouse; certain CH GRAT holdings are attributed to those trusts and his spouse, and he disclaims beneficial ownership of those particular shares.
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received an equity grant of 73,434 deferred stock units representing Class A common stock. These units are granted at no cash cost and increase his direct holdings to 207,352 shares after the award.
Each deferred stock unit gives the right to receive one Class A share. The units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Settlement into shares occurs on the earliest of December 31, 2031, a separation from service, a change in control, death, or disability, as defined under the company’s Deferred Compensation Plan for Directors.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Trevor Bezdek reported a compensation grant of 73,434 restricted stock units (RSUs), each representing one share of Class A common stock at a stated price of $0.00 per share. These RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Following this award, he holds 343,810 Class A shares directly and has additional indirect interests through TB 2024-2 GRAT and TB 2025 GRAT. Separate JB 2024-2 GRAT and JB 2025 GRAT positions, as well as one share held by his spouse, are associated with his spouse, and he disclaims beneficial ownership of those shares.
Wagner Scott reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Scott Wagner reported an equity award of 73,434 restricted stock units (RSUs) tied to Class A common stock. The RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to his continued service.
Each RSU represents a right to receive one share of Class A common stock at vesting, so this is a compensation-related grant rather than an open-market purchase. After this award, Wagner directly holds 290,097 Class A shares and is also associated with 182,900 shares held indirectly through the Wagner Family Trust.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported routine equity compensation activity involving restricted stock units that settled into Class A common stock. On June 15, 2026, he exercised RSUs representing 4,069 shares of Class A stock at a conversion price of $0.00 per share. To cover tax obligations, a total of 2,071 shares of Class A common stock were disposed of at approximately $2.65 per share through tax-withholding transactions, which are not open-market sales. The transactions reflect standard vesting and settlement of RSU awards rather than discretionary market purchases or sales.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Trevor Bezdek reported an equity award and updated holdings in Class A common stock. He received 110,294 restricted stock units, each representing one share, at a price of $0.00 per unit. These restricted stock units vest 100% on December 31, 2027, subject to his continued service.
Following this grant, Bezdek holds 270,376 shares of Class A common stock directly. The filing also lists indirect holdings by grantor retained annuity trusts TB 2024-2 GRAT and TB 2025 GRAT, where he is sole trustee and annuitant, as well as JB 2024-2 GRAT and JB 2025 GRAT, which are managed by his spouse and in which he has no pecuniary interest and disclaims beneficial ownership.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant and updated holdings in Class A common stock. On May 27, 2026, he received 4,642 deferred stock units at a price of $0.00 per share, bringing his directly held shares to 247,502.
The deferred stock units vest as to 2% of the underlying shares on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months. The units will settle in shares on the earliest of December 31, 2029, Separation from Service, a Change in Control, death, or Disability under the company’s Deferred Compensation Plan for Directors.
The filing also lists indirect holdings through several grantor retained annuity trusts and a spouse account. Hirsch disclaims pecuniary interest, voting, or investment control over shares held by the CH 2024-2 GRAT and CH 2025 GRAT established for his spouse.